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Aim To evaluate the impact of previously unrecognized 
negative interaction between the Wnt and interleukin (IL) 
6 signaling pathways in skeletal tissues as a possible major 
mechanism leading to age- and inflammation-related de-
struction of bone and joints.
Methods Luciferase reporter assays were performed to 
monitor Wnt pathway activation upon IL-6 and tumor ne-
crosis factor-α (TNFα) treatment. Functional contribution 
of IL-6 and TNFα interaction to inhibition of bone formation 
was evaluated in vitro using small hairpin RNAs (shRNA) in 
mouse mesenchymal precursor cells (MPC) of C2C12 and 
KS483 lines induced to differentiate into osteoblasts by 
bone morphogenetic proteins (BMP).
Results IL-6 inhibited the activation of Wnt signaling in 
primary human synoviocytes, and, together with TNFα 
and Dickkopf-1, inhibited the activation of Wnt response. 
ShRNA-mediated knockdown of IL-6 mRNA significantly in-
creased early BMP2/7-induced osteogenesis and rescued 
it from the negative effect of TNFα in C2C12 cells, as well as 
intensified bone matrix mineralization in KS483 cells.
Conclusion IL-6 is an important mediator in the inhibition 
of osteoblast differentiation by TNFα, and knockdown of 
IL-6 partially rescues osteogenesis from the negative con-
trol of inflammation. The anti-osteoblastic effects of IL-6 
are most likely mediated by its negative interaction with 
Wnt signaling pathway. Received: January 8, 2016
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Rheumatoid arthritis (RA) is a chronic systemic autoim-
mune inflammatory disorder that affects up to 1.8% of 
adult population of the world. This disease has a significant 
medical and social impact, since the absence of the effec-
tive treatment rapidly leads to reduced quality of patients’ 
lives and results in disability and even mortality. RA may 
affect many tissues and organs, but primarily attacks the 
synovium of joints. The process induces synovitis, synovial 
hyperplasia with neovascularization, and an excess of syn-
ovial fluid causing joint swelling, stiffness, and pain. This 
leads to a destruction of articular cartilage and multiple 
erosions into adjacent bones (1). Although RA has been 
the subject of numerous investigations, the cause of the 
disease is still unknown and its etiology and pathogenesis 
remain poorly understood (2).
Multiple cytokines regulate a broad range of inflamma-
tory processes implicated in RA pathogenesis. An imbal-
ance between the pro- and anti-inflammatory cytokine 
activities favors the induction of autoimmunity, chronic in-
flammation, and thereby joint damage (3). Tumor necro-
sis factor-α (TNFα), and interleukins IL-1β and IL-6 play the 
primary roles in the RA pathogenesis, as well as in other 
inflammatory diseases (1,4).
IL-6 can promote synovitis and joint destruction by stim-
ulating neutrophil migration, osteoclast maturation, and 
pannus formation. It may also mediate numerous systemic 
manifestations of RA, including joint erosions development 
as a result of IL-6 action toward osteoclasts and osteoblasts 
differentiation. On the other hand, it plays a positive regu-
latory role in osteoclast differentiation by inducing the ex-
pression of receptor activator of nuclear factor kappa-B li-
gand (RANKL) on the surface of osteoblasts (5-7).
Several signaling pathways are strongly misregulated in syn-
ovial fibroblasts, monocytes, neutrophils, endothelial, and 
other cells in the joints of RA patients. In particular, recent 
studies of human rheumatic and orthopedic diseases and 
specific mouse models with both activating and null mu-
tations of proteins required for the canonical Wnt signaling 
suggest this signaling cascade as one of crucially impor-
tant pathways in the regulation of bone formation, mainte-
nance, reparation, and remodeling by regulating osteoblast 
and osteoclast proliferation and differentiation (8-10). Os-
teoblast differentiation is predominantly induced by bone 
morphogenetic proteins (BMP), which are members of the 
transforming growth factor β (TGFβ) superfamily. However, 
efficient differentiation of mesenchymal precursors to the 
osteo- and chondrogenic lineages requires both Wnt and 
BMP signaling, and the canonical Wnt signaling pathway ap-
pears to be master regulator of osteogenesis (11).
Wnt/β-catenin signaling regulates osteogenesis through 
multiple mechanisms. Wnts repress alternative mesen-
chymal differentiation pathways, such as adipocyte and 
chondrocyte differentiation, and promote osteoblast dif-
ferentiation, proliferation, and mineralization activity while 
blocking osteoblast apoptosis. β-catenin represses osteo-
clastogenesis by increasing the ratio of osteoprotegerin 
(OPG)/RANKL (12). In a healthy skeleton, formation and re-
sorption of adjacent to joints cortical bones are well bal-
anced but inflammatory arthritis leads to an imbalance 
between these processes. Bone formation is hampered by 
the TNF-mediated expression of Dickkopf-1 (DKK-1), which 
suppresses Wnt signals, whereas bone resorption is en-
hanced by the expression of RANKL – a key factor in the os-
teoclast differentiation and activation. DKK-1 is critical for 
joint remodeling. Blockade of DKK-1 relieves Wnt signaling 
from DKK-1-mediated suppression and induces bone for-
mation mirrored by the growth of osteophytes (13).
In terms of the commitment and differentiation of mesen-
chymal stem cells (MSC), there is a cooperative crosstalk 
between the Wnt and BMP pathways (14). BMP signaling 
is crucial for osteogenesis and skeleton homeostasis dur-
ing both embryogenesis and postnatal life. The crosstalk 
between BMP and Wnt signaling is complex in all tissues, 
and it can be either synergistic or antagonistic depending 
on the cellular context. In line with the complexity of their 
crosstalk, BMP and Wnt signaling have opposing effects on 
the osteoprogenitors, yet for the most part they seem to 
function cooperatively in osteoblasts and osteocytes.
Although a crucial role for canonical Wnt signaling in skel-
eton homeostasis has been strongly established, much re-
mains to be discovered in respect to its fine tuning and 
crosstalk with other pathways in bone (15). The main aim 
of this study was to evaluate the impact of previously un-
recognized negative interaction between the Wnt and IL-6 
signaling pathways in skeletal tissues as a possible major 
mechanism leading to age- and inflammation-related de-
struction of bone and joints.
MateRiaLS anD MethODS
Cell culture and ligands
Our studies were performed using mouse NIH-3T3 fibro-
blasts and mouse mesenchymal precursor cells of C2C12 
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and KS483 lines. These cells were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM, Sigma) containing 10% 
fetal calf serum (FCS, Sigma). Cells were grown in a 5% 
CO2-containing atmosphere at 37°C. Upon transient trans-
fection, cells were grown in DMEM supplemented with 
4% FCS and 16 hours later, they were transferred to fresh 
DMEM with 10% FCS and addition of appropriate ligands. 
In particular, cells in appropriate variants were treated 
with 10 ng/mL of recombinant TNFα, 100 ng/mL of IL-6 in 
combination with 500 ng/mL of soluble IL-6R. All ligands 
were purchased from R&D Systems (Minneapolis, MN, 
USA). Alternatively, in some experiments IL-6/IL-6R combi-
nation was substituted with HyperIL-6 fusion protein (10 
ng/mL) (16,17).
Primary human synoviocytes (fibroblast-like synoviocytes, 
FLS) were isolated from synovial biopsies of patients with 
RA fulfilling the American College of Rheumatology re-
vised criteria for RA (18,19), cultured as previously de-
scribed (20) and used for experiments between passages 
4 and 9, following overnight culture in the medium con-
taining 1% fetal bovine serum (FBS; Invitrogen, Breda, The 
Netherlands).
Materials
Short (small) hairpin RNA (shRNA)-expressing constructs 
are frequently used as a convenient substitution for siRNA 
specifically targeting gene expression that allows to avoid 
initial side effects of transfection required for siRNA de-
livery to the cells. A set of validated shRNA lentiviral con-
structs that specifically target the expression of mouse 
versions of IL-6 mRNAs was purchased as a part of MIS-
SION library from Sigma-Aldrich (St. Louis, MS, USA). Hy-
per-IL-6, which is a fusion protein of human IL-6 fused to 
the soluble human IL-6R (16), was prepared as described 
previously (17).
Plasmids expressing BMP2 and BMP7 full-length cDNA 
were purchased from Open Biosystems/GE Healthcare 
(Lafayette, CO, USA). pPGK-mWnt3a-neo plasmid was 
kindly provided by Drs. Ritsuko and Shinji Takada. MIS-
SION shRNA lentiviral constructs targeting mouse IL-6 
were purchased from Sigma-Aldrich (St. Louis, MS, USA). 
Wnt signaling-specific reporter Bat-Luc and pCMV-DKK-1 
plasmids were kindly provided by Dr Stefano Piccolo. 
pShuttle, pShuttle-CMV, and Easy1 plasmids (components 
of AdEasy system developed for generation of recombi-
nant adenoviruses described below) were provided by Dr 
Bert Vogelstein.
Generation of recombinant adenoviral vectors
BMP2, BMP7, Wnt3a, and Bat-Luc adenoviruses were pre-
pared and grown as described previously (20). Briefly, to 
generate BMP2, BMP7, and Wnt3a adenoviruses, the full-
length cDNA was recloned into pShuttle-CMV plasmid. A 
pShuttle vector was used in order to make a Bat-Luc re-
porter adenovirus. Obtained pShuttle or pShuttle-CMV 
constructs were linearized with PmeI restrictase and re-
combined with Easy-1 vector. Resulting cosmids were lin-
earized with PacI restrictase and prepared as adenoviruses 
in HEK-293 cells (20).
transient transfection
C2C12 and KS483 cells were split at a density of 1.5 × 104 
cells per cm2 in 12-well plates. The following day, cells 
were transiently transfected with plasmid constructs ex-
pressing shRNA targeting IL-6 mRNA or control scrambled 
shRNA (0.5 µg of total DNA per well). Transfection was 
carried out using GeneJuice transfection reagent (Merck 
Millipore, Billerica, MA, USA) following the manufacturer’s 
protocol. The efficacy of shRNA-mediated knockdown 
was confirmed by quantitative polymerase chain reaction 
(PCR) and varied from 6.5 to 8 times for most efficient vari-
ants (data not shown).
For luciferase reporter assays, NIH-3T3 cells were split at a 
density of 1.5 × 104 cells per cm2 in 12-well plates. Trans-
fection was carried out using polyethyleneimine reagent 
(Polysciences, Warrington, PA, USA). pcDNA3 plasmid (In-
vitrogen) was used as a control vehicle. Co-transfection 
with pCMV-β-Gal plasmid (Clontech-Takara, Mountain 
View, CA, USA) was used as an internal control for the ef-
ficacy of transient transfection. β-Galactosidase activity in 
cellular lysates was quantified spectrophotometrcally in 
100 mmNa2HPO4/NaH2PO4, 1 mm MgCl2, 100 mm 2-mer-
captoethanol, and 0.67 mg/mL O-nitrophenylgalactopyra-
noside essentially as before (21).
Luciferase reporter assays
FLS cells were split at a density of 1 × 104 cells per cm2 in 12-
well plates. The following day, cells were transiently trans-
fected with Bat-Luc reporter adenovirus ([MOI] MO = 200) 
in a combination with β-Gal adenovirus to be used as an 
internal control for the efficacy of transduction (MOI = 20). 
12 hours later, cellular monolayer was rinsed with a serum-
free medium and cells in appropriate variants were trans-
duced with Wnt3a adenovirus or GFP adenovirus at total 
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MOI = 500. After next 12 hours later cellular monolayer was 
rinsed with a serum-free medium, re-fed with fresh com-
plete culture medium and treated with indicated ligands 
for next 48 hours. Luciferase reporter assays were conduct-
ed using luciferase reporter assay reagent (Promega, Madi-
son, WI, USA) on a Victor 3 machine (Perkin Elmer, Waltham, 
MA, USA) essentially as before (21).
Stable infection
C2C12 cells were plated in a complete media overnight. 
Lentiviral particles were added at MOI = 5 and = 10 in the 
presence of DEAE-dextran, and cells were incubated for 24 
hours. Then, equal amount of fresh media with no lentivi-
rus was added, and the cells were incubated for additional 
24 hours. Two days later, transduced cells were selected by 
adding 3-4 µg/mL of puromycin (Sigma). Obtained puro-
mycin-resistant multi-clonal cultures of C2C12 cells were 
used. These cells were tested for the presence of the lenti-
viral p24 using ELISA, and no p24 was detected. An efficacy 
of shRNA knockdown was confirmed with a Real-Time RT-
PCR amplification (data not shown).
induction of osteoblast differentiation
C2C12 and KS483 cell lines can be induced to differenti-
ate into osteoblasts by different BMPs, including BMP2 
and BMP7. 24 hours after transient transfection, these 
cells lines were transduced with a combination of aden-
oviral constructs encoding recombinant BMP2 and BMP7 
at the multiplicity of infection (MOI) even to 500 for each 
one construct (22) to induce a production of BMP2/BMP7 
heterodimers along with appropriate homodimers. Dur-
ing osteogenesis assay, C2C12 and KS483 cells were cul-
tured in a differentiation-supporting medium supple-
mented with 50 µg/mL ascorbic acid for 4 and 10 days, 
respectively. Starting from day 10 upon induction of osteo-
genesis, KS483 cells were also supplemented with 5 mM 
β-glycerophospate for next 8 days totaling in 18 days. Re-
combinant BMPs were a gift from Dr K. Sampath (Curis Inc., 
Cambridge, MA, USA).
alkaline phosphatase assay
The alkaline phosphatase activity produced by 
C2C12 was analyzed spectrophotometrically using a 
π-nitrophenylphosphate (π-NPP) as a substrate (23). Four 
days after the induction of osteogenesis, the cells were 
washed twice with 0.4 mL of 1X phosphate-buffered sa-
line (PBS) per well. Afterwards, cells were lysed in 0.2 mL 
of alkaline phosphatase (ALP) lysis buffer (10 mM gly-
cine, 100 µM MgCl2, 10 µM ZnCl2, 0.1% Triton X-100) per 
well and agitated gently for 5 min. Then, 10 µL aliquot of 
cell lysate was placed into a 96-well plate and ALP activ-
ity was revealed with 90 µL/well of ALP assay buffer (100 
mM glycine, 1 mM MgCl2, 100 µM ZnCl2) supplemented 
with 6 mM π-NPP (Pierce-Thermo Fisher Scientific, Grand 
Island, NY, USA) (24). Cell lysate samples were mixed gently 
with a mentioned above reaction buffer and incubated at 
room temperature until color developed. Optical density 
was measured at 405 nm (OD405) in a 96-well plate reader 
(BioTek, Winooski, VT, USA).
alizarin staining
Histochemical examination of mineral deposition by KS483 
cells was performed using conventional staining with Aliz-
arin Red (Sigma-Aldrich) (23). Cellular monolayers were 
washed with 1X PBS (0.4 mL/well) and fixed in 10% (v/v) 
formaldehyde at room temperature for 5 min. The mono-
layers were then washed with deionized H2O (dH2O) prior 
to addition of 0.4 mL of 2% Alizarin Red S solution (pH 5.5) 
per well. The plate was incubated at room temperature for 
2-5 min with gentle agitation. After aspiration of the unin-
corporated dye, the wells were washed twice shortly with 
0.4 mL of dH2O per well and once with 3 mL of dH2O per 
well while shaking for 5 and 20 min, respectively. Then, the 
monolayers were stored in 1 mL of 1X PBS and scanned.
Statistical analysis
Results of luciferase reporter activation and spectropho-
tometric measurements of alkaline phosphatase activity 
are expressed as mean ± standard deviation. Data were 
analyzed using GraphPad Prism 6 program. Statistical dif-
ferences between experimental variants were assessed 
by non-parametric two-way ANOVA. Appropriate P values 
were shown in graphs to demonstrate the significance of 
the results. Only differences with P-values lower than 0.05 
were regarded as significant.
ReSuLtS
iL-6 together with tnFα inhibits the activation of Wnt 
pathway in primary human synoviocytes
In primary human synoviocytes, both TNFα and IL-6 in-
hibited the activation of Wnt signaling induced with the 
overexpression of Wnt3a adenovirus (Figure 1A). The TNFα 
inhibition was respectively 2.1 and 2.7 times when Wnt3a 
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adenovirus was used at MOI = 300 and 500. The IL-6 inhibi-
tion was more pronounced: respectively 3.2 and 4.4 times 
when Wnt3a was used at MOI = 300 and 500 (Figure 1A). 
Strikingly, these two proinflammatory cytokines together 
inhibited the activation of Wnt3a response (respectively 
13.1 and 14.5 times when Wnt3a was used at MOI = 300 
and 500, Figure 1A). The experiment was repeated with FLS 
cells obtained from two more different RA patients with 
the same trends, but with different magnitudes of induc-
tion/inhibition (data not shown).
iL-6 together with DKK-1 or tnFα inhibits the activation 
of Wnt pathway in nih-3t3 fibroblasts
Mouse fibroblasts of NIH-3T3 line were much less respon-
sive to the inhibitory effects of TNFα than human FLS and 
without stimulation with Wnt3a did not respond to IL-6 (Fig-
ure 1B). Nevertheless, in NIH-3T3 cells the combination of 
IL-6/IL-6R with TNFα showed a cooperative inhibitory effect. 
We also combined the inhibitory effects of IL-6/IL-6R, TNFα 
or their combination with the overexpression of DKK-1, a 
master Wnt signaling inhibitor. IL-6 together with DKK-1 
inhibited Wnt response, while a combination of all three 
agents (IL-6/IL-6R, TNFα, and DKK-1) was less efficient than 
the combination of IL-6 and DKK-1 (Figure 1B). Moreover, 
TNFα did not show any effect in combination with DKK-1 or 
in combination with IL-6/IL-6R and DKK-1 together.
ShRna-mediated knockdown of iL-6 expression 
potentiates and rescues osteoblast differentiation from 
the negative effect of tnFα
While taking into account that RA progression in joints af-
fects also adjacent bones, we further performed an in vitro 
evaluation of functional contribution of IL-6 and TNFα on 
the inhibition of bone formation using treatment with re-
combinant cytokines combined with a blocking of IL-6 ex-
pression by shRNA in mouse mesenchymal precursor cells 
of C2C12. ALP is a widely used marker of early stages in os-
teoblast differentiation (25-27), and we successfully used 
it in our study. Treatment of C2C12 cells with TNFα com-
pletely inhibited their myoblast differentiation, as well as 
strongly inhibited BMP-induced osteogenesis (Figure 2A 
and data not shown).
Transient overexpression of shRNA targeting IL-6 mRNA, 
similarly to many other small interfering (siRNA) and shR-
NA, always induces some off-target interferon response. 
At the same time, efficient shRNA constructs allowed to 
partially (anti-IL-6 shRNA-1) rescue the osteogenic differ-
entiation from negative effect of TNFα. In case of use an 
anti-IL6 shRNA-2 TNFα was even converted from an inhib-
itor into a potentiator of osteogenesis (data not shown 
and Figure 2A).
FiGuRe 1. interleukin-6 (iL-6) together with tumor necrosis factor α inhibits the activation of Wnt signaling pathway in primary 
synovial fibroblasts (A) and iL-6 cooperates with Dickkopf-1 and tumor necrosis factor α (tnFα) in the inhibition of Wnt3a pathway in 
mouse fibroblasts of nih-3t3 line (B). Wnt response was induced with Wnt3a adenovirus and later cells were treated with a combina-
tion of recombinant iL-6 (100 ng/mL) and its receptor iL-6R (500 ng/mL) or 10 ng/mL of recombinant tnFα, or with the combination 
of all three recombinant proteins for the next 48 hours. Relative luciferase units are shown.
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Therefore, we generated lentivirally transduced multi-
clonal cultures of C2C12 and KS483 cells with stable ex-
pression of shRNAs that specifically target the expression 
of IL-6 mRNA and scrambled shRNA to be used as a con-
trol. shRNA-mediated knockdown of IL-6 increased BMP2/
BMP7-induced osteoblast differentiation (in individual 
experiments from 2.7 to 6 times compared with the con-
trol) in stable multi-clonal cultures of C2C12 (Figure 2A) 
and KS483 cells (Figure 2B). At the same time, similarly 
to activation of Wnt pathway in NIH-3T3 cells (Figure 1B), 
HyperIL-6 treatment alone did not influence early osteo-
blast differentiation of KS483 cells (Figure 2B). Unfortu-
nately, we were not able to combine BMP2/BMP7 treat-
ment with TNFα due to massive death induced in KS483 
cells by TNFα (data not shown). Similar effect was also ob-
served by other investigators with other (pre)osteoblastic 
cell lines (24,28).
ALP cannot be used as a marker for late stages of osteo-
blast differentiation for which bone mineral deposition 
and nodules formation are specific. According to literature 
and to our preliminary data (not shown), Wnt pathway is 
activated during late stages of osteoblast differentiation 
(29). Unfortunately, C2C12 cells cannot undergo late stag-
es of osteoblast differentiation. Therefore, in order to con-
firm the proper functional outcome of IL-6 inactivation in 
FiGuRe 2. ShRna-mediated knockdown of Interleukin 6 expression potentiates and rescues early osteoblast differentiation from the 
negative effect of tumor necrosis factor α (tnFα) in stable multi-clonal cultures of C2C12 cell line (A) and intensifies bone morphoge-
netic proteins 2/7 (BMP2/7)-induced osteogenesis in stable multi-clonal cultures of KS483 cell line (B). Stable lentivirally transduced 
multi-clonal cultures of C2C12 (A) and KS483 (B) cells were split into 12-well plates and treated with a mixture of recombinant BMP2 
and BMP7 adenoviruses to induce there osteoblast differentiation. 10 ng/mL of recombinant tnFα or 10 ng/mL of recombinant 
hyperiL-6 were used to modulate osteoblast differentiation. alkaline phosphatase activity in cell lysates was analyzed spectrophoto-
metrically. Optical density at 405 nm is shown.
FiGuRe 3. ShRna-mediated knockdown of Interleukin 6 expression intensifies bone morphogenetic protein 2/7-induced bone matrix 
mineralization in KS483 mouse mesenchymal precursor cells. KS483 cells were ectopically transduced with indicated shRna plas-
mids (0.5 µg of total Dna per well). Osteoblast differentiation was triggered with the combination of adenoviral constructs encoding 
recombinant BMP2 and BMP7 for 18 days. Cells were fixed and stained with alizarin Red. Representative fields (1 × ) are shown.
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differentiating osteoblasts, we used KS483 cells that can ef-
ficiently follow late stages of osteogenesis (23).
The treatment of KS483 cells with BMP2/BMP7 strongly 
intensified their late osteoblast differentiation and over-
expression of a combination of 6 versions of shRNA con-
structs targeting IL-6 further potentiated osteogenesis. 
More efficient differentiation was observed through both 
nodules formation (data not shown) and matrix mineral-
ization when compared with a control scrambled shRNA 
(Figure 3).
DiSCuSSiOn
The current study showed for the first time that IL-6 in-
hibited the activation of Wnt signaling pathway in prima-
ry synoviocytes derived from RA patients. The hypothesis 
about such crosstalk arises from accumulated data taking 
into account that IL-6 is a well-known target gene for both 
TNFα and IL-1β (1,4), and Wnt pathway was recently recog-
nized as a master regulator of joint remodeling (13). Even 
more intriguing is the cooperation between IL-6 and TNFα 
in the inhibition of Wnt signals because anti-IL-6 therapy 
appeared to be an important alternative treatment for pa-
tients who are not responsive to TNF blockers (30,31).
Interestingly, we found regular NIH-3T3 fibroblasts to be 
poorly responsive to Wnt3a effects as well as to TNFα treat-
ment. A much lower sensitivity of NIH-3T3 fibroblasts to 
inhibitory effects of IL-6 combinations with TNFα and with 
DKK-1 allowed us to speculate that much higher sensitivity 
of FLS cells represented a cell type-specific feature of these 
cells that was important for RA development and progres-
sion. A similar striking cell type-specific difference is also 
found in the regulation of presumable RA associated gene, 
PADI4 (32) and activation of its promoter (data not shown). 
Moreover, TNFα did not show any effect in combination 
with DKK-1 and in combination with two other agents 
(IL-6/IL-6R and DKK-1). Such absence of TNFα effects sug-
gests an overlapping mechanism as it was proposed by Di-
arra et al (13), who found DKK-1 to be a master regulator 
of join remodeling. Our speculation about cell-specific fea-
ture of FLS cells is also supported with the result of direct 
HyperIL-6 treatment in KS483 cells, in which we observed 
a significant potentiation of early osteoblast differentiation 
upon shRNA knockdown of IL-6 mRNA. It is still possible 
that the best results could be obtained with a combined 
treatment of these cells with HyperIL-6 and DKK-1 since in-
teraction with TNFα-induced DKK-1 could serve as a cen-
tral mechanism mediating IL-6 effects on the inhibition 
of osteoblast differentiation. Interestingly, RA progression 
FiGuRe 4. impact of iL-6/Wnt interaction in joint remodeling. inflammation inhibits BMP-Smad response and functional activity of its 
target gene RunX2, which is important in osteoblast differentiation. tnFα induces both iL-6 and DKK-1 expression. the cooperation 
of iL-6 and DKK-1 genes is important in inflammatory control of Wnt response and joint remodeling.
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lowers osteoprotegerin/RANKL ratio and increases circulat-
ing RANKL level that correlates positively with C-reactive 
protein. DKK-1, sclerostin, and osteocalcin levels were also 
increased with RA progression (30). On the other hand, 
the anti-IL6 therapy in patients decreases DKK-1 levels in 
patients’ sera (30). Surprisingly, a similar study performed 
with the synovial fluids and inflamed joints tissues (31) has 
found an inverse correlation between the DKK-1 levels and 
IL-6 levels observed in vivo in the inflamed joints. However, 
these studies only describe the changes without explain-
ing the possible mechanism behind these changes, and 
our study is the first one that provides a possible explana-
tion for the mechanism.
We showed that knockdown of IL-6 partially rescued osteo-
genesis from the negative control of inflammation. Such a 
result suggests that IL-6 is an important mediator in the in-
hibition of osteoblast differentiation by TNFα. Despite the 
fact that IL-6 and TNFα are well recognized as the key cy-
tokines in RA pathogenesis the precise mechanism of how 
IL-6 and TNFα interaction inhibits bone formation is still 
not fully understood and a proper understanding of such 
molecular mechanism(s) for functional contribution of IL-6 
and TNFα interaction into inhibition of bone formation is 
critically important.
Taking into account the known data, it was unexpected 
that TNFα was converted into an activator of osteoblast 
differentiation upon shRNA knockdown of IL-6 expression. 
This showed that activation/inhibition and regulation of 
osteogenesis are poorly understood, in particular during 
inflammation or due to aging. It is a complex system that 
includes many components and interactions and many of 
them are still unknown.
We also showed that IL-6 was an important inhibitor of late 
osteogenesis, which can be explained by the existence of 
a still unknown direct or indirect negative interaction be-
tween IL-6 and Wnt signaling pathways, in which DKK-1 
plays an important role (Figure 4) (13,30,31). The Wnt sig-
naling pathway inhibition by this cytokine in skeletal tis-
sues is a possible major mechanism leading to age- and 
inflammation-related bone and joints destruction.
Thus, our data as well as results of other investigators allow 
us to hypothesize that the crosstalk between IL-6 and Wnt 
signaling pathways represents a novel key mechanism for 
regulation of the homeostasis of joint tissues involved in 
pathogenesis of RA and osteoporosis progression. Our 
understanding of the precise molecular mechanisms and 
functional impact of inhibition of Wnt signaling pathway 
by IL-6 is crucial for proper understanding of its role in the 
RA and osteoporosis pathogenesis and progression. Be-
sides this, understanding of these mechanisms can be-
come a basis for development of novel strategies in diag-
nostics and treatment of this and other related disorders.
In conclusion, IL-6 cooperates with TNFα and DKK-1 in the 
inhibition of osteogenic Wnt signaling, which is important 
for joint remodeling. Therefore IL-6 is an important medi-
ator in the inhibition of osteoblast differentiation by the 
TNFα, and knockdown of IL-6 partially rescues osteogen-
esis from negative control of inflammation. The anti-osteo-
blastic effects of IL-6 in RA are most likely mediated by its 
negative interaction with Wnt signaling pathway.
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